

Drug Policy:

Faslodex™ (fulvestrant)

POLICY NUMBER UM ONC_1039	SUBJECT Faslodex™ (fulvestrant)		DEPT/PROGRAM UM Dept	PAGE 1 OF 3
DATES COMMITTEE REVIEWED 01/12/11, 03/08/12, 10/30/13, 03/05/15, 04/11/16, 02/06/17, 01/10/18, 02/13/19, 12/11/19, 02/12/20, 04/08/20, 02/10/21, 11/15/21, 01/12/22, 05/11/22, 01/11/23	APPROVAL DATE January 11, 2023	EFFECTIVE DATE January 27, 2023	COMMITTEE APPROVAL DATES 01/12/11, 03/08/12, 10/30/13, 03/05/15, 04/11/16, 02/06/17, 01/10/18, 02/13/19, 12/11/19, 02/12/20, 04/08/20, 02/10/21, 11/15/21, 01/12/22, 05/11/22, 01/11/23	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
URAC STANDARDS HUM v8: UM 1-2; UM 2-1	NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Faslodex (fulvestrant) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
2. When health plan Exchange coverage provisions-including any applicable PDLs (Preferred Drug Lists)-conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)

3. When Health Plans utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, and there is no Health Plan PDL applicable, the [Preferred Drug Guidelines](#) shall follow NCH recommended agents/regimens/preferred drugs **AND**
4. Continuation requests of previously approved, non-preferred medication are not subject to this provision **AND**
5. When applicable, generic alternatives are preferred over brand-name drugs **AND**
6. When there is a documented drug shortage, disease progression, contraindication, or confirmed intolerance to a preferred drug/regimen, per NCH Policy and Pathway, the available alternative product may be used if deemed medically appropriate and the indication is listed in a standard reference compendia or accepted peer review literature. For a list of current drug shortages, please refer to FDA drug shortage website in the reference section.

B. Breast Cancer

1. The member has advanced or metastatic hormone receptor (ER/PR) positive breast cancer and is post-menopausal or if the member is pre-menopausal and receiving concomitant ovarian ablation/suppression, Faslodex (fulvestrant) may be used as **ANY** of the following:
 - a. In combination with an aromatase inhibitor (e.g., anastrozole, letrozole).
 - b. In combination with Afinitor (everolimus) as second line or subsequent line of therapy
 - c. In combination with a CDK4/6 inhibitor e.g., palbociclib, abemaciclib, ribociclib.
 - d. In combination with Piqray (alpelisib), if tumor is PIK3CA mutation positive, as second line therapy or subsequent line of therapy.
 - e. In combination with trastuzumab for HER2 positive disease.
 - f. As a single agent.

III. EXCLUSION CRITERIA

- A. The member is a premenopausal female who is not receiving concomitant ovarian ablation/suppression.
- B. The member has hormone receptor negative tumor.
- C. Dosing exceeds single dose limit of 500 mg.
- D. Investigational use of Faslodex (fulvestrant) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 4. Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).

5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES

- A. Slamon DJ, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol*. 2018 Aug 20;36(24):2465-2472.
- B. Sledge GW Jr, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol*. 2017 Sep 1;35(25):2875-2884.
- C. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med* 2018;379:1926-36.
- D. Faslodex prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington, DE 2020.
- E. Clinical Pharmacology Elsevier Gold Standard 2023.
- F. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, CO 2023.
- G. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.
- H. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2023.
- I. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
- J. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
- K. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.
- L. NCQA UM 2023 Standards and Elements.